Lab Location: Anna Spiegel Center of Translational Research, Level 5
Associated Clinical Department: General Surgery

Contact: michael.bergmann@meduniwien.ac.at.
Tel. ++43-1-40400-73744

In particular we are investigating the role of therapy-induced (i.e. chemotherapy, radiotherapy) biological changes in the tumor-immune microenvironment (TIME) of human solid malignancies, such as colorectal cancer (CRC) or colorectal liver metastases (CLM), in a human-translational setting. The research aims are to examine the induction and consequences of a therapy-induced endoplasmic reticulum (ER) stress response, immunogenic cell death (ICD), type I and type II interferon (IFN) induction on tumor-infiltrating immune cells with clinical outcome. Our goal is to develop novel concepts of cancer immunotherapy, using a rational combined treatment approach.
Corresponding techniques are used to investigate immune related pathways in inflammatory bowel disease. Here we focus on the impact of receptors mediating cell death, gamma-delta T-cells and on metabolic changes observed in immune cells. 
Having an expertise in genetic engineering of influenza A virus, we developed the first oncolytic influenza A virus. Currently our aim is to further optimize its viral vectors and production to facilitate a routine clinical application.